BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $14.96 billion. The enterprise value is $16.80 billion.
Important Dates
The last earnings date was Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 194.80 million shares outstanding. The number of shares has increased by 2.39% in one year.
| Current Share Class | 194.80M |
| Shares Outstanding | 194.80M |
| Shares Change (YoY) | +2.39% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 3.95% |
| Owned by Institutions (%) | 95.71% |
| Float | 163.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.75 |
| Forward PS | 10.13 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09
| Current Ratio | 2.09 |
| Quick Ratio | 1.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -13.97% |
| Return on Invested Capital (ROIC) | -17.67% |
| Return on Capital Employed (ROCE) | -29.81% |
| Weighted Average Cost of Capital (WACC) | 8.59% |
| Revenue Per Employee | $871,465 |
| Profits Per Employee | -$545,737 |
| Employee Count | 1,085 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, BBIO has paid $1.11 million in taxes.
| Income Tax | 1.11M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.68% in the last 52 weeks. The beta is 0.94, so BBIO's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +15.68% |
| 50-Day Moving Average | 70.07 |
| 200-Day Moving Average | 72.69 |
| Relative Strength Index (RSI) | 59.54 |
| Average Volume (20 Days) | 2,975,165 |
Short Selling Information
The latest short interest is 20.85 million, so 10.70% of the outstanding shares have been sold short.
| Short Interest | 20.85M |
| Short Previous Month | 20.00M |
| Short % of Shares Out | 10.70% |
| Short % of Float | 12.79% |
| Short Ratio (days to cover) | 7.35 |
Income Statement
In the last 12 months, BBIO had revenue of $945.54 million and -$592.13 million in losses. Loss per share was -$3.04.
| Revenue | 945.54M |
| Gross Profit | 892.00M |
| Operating Income | -353.11M |
| Pretax Income | -576.47M |
| Net Income | -592.13M |
| EBITDA | -348.36M |
| EBIT | -353.11M |
| Loss Per Share | -$3.04 |
Full Income Statement Balance Sheet
The company has $1.54 billion in cash and $3.38 billion in debt, with a net cash position of -$1.84 billion or -$9.44 per share.
| Cash & Cash Equivalents | 1.54B |
| Total Debt | 3.38B |
| Net Cash | -1.84B |
| Net Cash Per Share | -$9.44 |
| Equity (Book Value) | -1.65B |
| Book Value Per Share | -13.29 |
| Working Capital | 1.07B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$368.97 million and capital expenditures -$835,000, giving a free cash flow of -$369.81 million.
| Operating Cash Flow | -368.97M |
| Capital Expenditures | -835,000 |
| Depreciation & Amortization | 4.74M |
| Net Borrowing | 576.89M |
| Free Cash Flow | -369.81M |
| FCF Per Share | -$1.90 |
Full Cash Flow Statement Margins
Gross margin is 94.34%, with operating and profit margins of -37.34% and -59.84%.
| Gross Margin | 94.34% |
| Operating Margin | -37.34% |
| Pretax Margin | -60.97% |
| Profit Margin | -59.84% |
| EBITDA Margin | -36.84% |
| EBIT Margin | -37.34% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.39% |
| Shareholder Yield | -2.39% |
| Earnings Yield | -3.95% |
| FCF Yield | -2.48% |
Dividend Details Analyst Forecast
The average price target for BBIO is $107.00, which is 39.32% higher than the current price. The consensus rating is "Buy".
| Price Target | $107.00 |
| Price Target Difference | 39.32% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 72.28% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -0.04 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.04 |
| Piotroski F-Score | 2 |